Vittoria Biotherapeutics, Inc.

Overview

Vittoria Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to address the limitations of current cell therapy approaches, especially in treating difficult-to-treat diseases in oncology and autoimmune disorders.

Central to its work is the proprietary Senza5™ platform technology, which enhances the effectiveness of engineered T cells by modulating CD5 signaling. The platform features a rapid five-day manufacturing process aimed at improving production efficiency and maximizing T cell stemness, durability, and potency. The company’s lead product candidate, VIPER-101, is undergoing Phase 1 clinical trials for recurrent nodal peripheral T-cell lymphoma. Its pipeline includes therapies targeting solid tumors and autoimmune diseases, demonstrating a commitment to transforming patient treatment options and actively advancing clinical research.

Basic Information

Industry	research
Founded	2021
Revenue	400K
Headquarters	3675 Market St, Suite 200, Philadelphia, Pennsylvania 19104, United States

Contact Details

Phone: +1 215-600-1380
Website: vittoriabio.com
LinkedIn: linkedin.com/company/vittoriabio

Key Focus Areas & Initiatives

CAR T-cell therapy for oncology and autoimmune disorders
Senza5™ platform technology for engineered T cells
Rapid five-day cell manufacturing process
VIPER-101 clinical trials (autologous CAR T-cell therapy)
CD5 signaling modulation in cell therapy
Therapies targeting solid tumors and autoimmune diseases
T-cell stemness, potency, and durability enhancement
Clinical-stage immunotherapy development
Pipeline for challenging cancers and immune conditions
Active recruitment in clinical trials

Technologies Used

Google Analytics
Google Tag Manager
Gravity Forms
Microsoft Office 365
Mobile Friendly
Outlook
WordPress.org

Affiliated Organizations & Regional Branches